Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Stock Down 3.5 %
Shares of NASDAQ:FENC traded down $0.24 during trading on Tuesday, reaching $6.69. 36,448 shares of the stock were exchanged, compared to its average volume of 37,786. The company has a debt-to-equity ratio of 0.36, a current ratio of 8.96 and a quick ratio of 8.96. Fennec Pharmaceuticals has a 1-year low of $3.37 and a 1-year high of $7.59. The stock has a fifty day moving average of $6.14 and a two-hundred day moving average of $5.73. The firm has a market cap of $174.39 million, a price-to-earnings ratio of -10.62 and a beta of 0.09.
Fennec Pharmaceuticals (NASDAQ:FENC - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts anticipate that Fennec Pharmaceuticals will post -0.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Wedbush reissued an "outperform" rating on shares of Fennec Pharmaceuticals in a research note on Wednesday, April 27th. Craig Hallum reissued a "buy" rating and issued a $14.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday.